Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Malabsorption Syndromes D008286 16 associated lipids
Pregnancy Complications, Cardiovascular D011249 11 associated lipids
Thrombasthenia D013915 4 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Disseminated Intravascular Coagulation D004211 7 associated lipids
Shock, Traumatic D012774 4 associated lipids
Hemorrhagic Fever, American D006478 2 associated lipids
Fetal Growth Retardation D005317 9 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Arthus Reaction D001183 8 associated lipids
Thrombocytosis D013922 4 associated lipids
Toxemia D014115 3 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina, Unstable D000789 14 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Klebsiella Infections D007710 7 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Hyperinsulinism D006946 27 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Parkinson Disease D010300 53 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Salmonella Infections, Animal D012481 9 associated lipids
Bronchial Diseases D001982 3 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Tangier Disease D013631 8 associated lipids
Heart Arrest D006323 13 associated lipids
Cystitis D003556 23 associated lipids
Cholecystitis D002764 8 associated lipids
HIV Infections D015658 20 associated lipids
Subacute Sclerosing Panencephalitis D013344 3 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Medulloblastoma D008527 22 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Hypertension, Portal D006975 12 associated lipids
Atherosclerosis D050197 85 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Dyslexia D004410 3 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Shukla SD and Hanahan DJ An early transient decrease in phosphatidylinositol 4,5-bisphosphate upon stimulation of rabbit platelets with acetylglycerylether phosphorylcholine (platelet activating factor). 1983 Arch. Biochem. Biophys. pmid:6320731
Wasserman SI Mediators of immediate hypersensitivity. 1983 J. Allergy Clin. Immunol. pmid:6193157
MacIntyre DE and Pollock WK Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets. 1983 Biochem. J. pmid:6411067
Larsen GL and Henson PM Mediators of inflammation. 1983 Annu. Rev. Immunol. pmid:6399978
Albert DH and Snyder F Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation. 1983 J. Biol. Chem. pmid:6401298
McManus LM et al. Thromboxane B2 (TxB2) release following acetyl glyceryl ether phosphorylcholine (AGEPC) infusion in the rabbit. 1983 Immunopharmacology pmid:6832960
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Ninio E et al. Biosynthesis of platelet-activating factor (PAF-acether). V. Enhancement of acetyltransferase activity in murine peritoneal cells by calcium ionophore A23187. 1983 Biochim. Biophys. Acta pmid:6405792
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
O'Flaherty JT et al. 5-L-hydroxy-6,8,11,14-eicosatetraenoate potentiates the human neutrophil degranulating action of platelet-activating factor. 1983 Biochem. Biophys. Res. Commun. pmid:6403011
Drapier JC et al. Lipid-mediator synthesis in peritoneal macrophages from mice injected with immunostimulants. 1983 Biochim. Biophys. Acta pmid:6131693
Otsuka A et al. alpha-Adrenergic blocking action of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats. 1983 Clin Exp Hypertens A pmid:6133661
Jouvin-Marche E et al. Effect of the Ca2+ antagonist nifedipine on the release of platelet-activating factor (PAF-acether), slow-reacting substance and beta-glucuronidase from human neutrophils. 1983 Eur. J. Pharmacol. pmid:6134631
Hopkins NK et al. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4. 1983 Biochim. Biophys. Acta pmid:6313071
Haddad ZH and Green A State--and dynamics--of the art: a current review. IgE-mediated immediate hypersensitivity reactions: cellular events and pharmacologic mediators. 1983 J Asthma pmid:6190793
Czarnetzki B Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. 1983 Clin. Exp. Immunol. pmid:6317241
Stimler NP and O'Flaherty JT Spasmogenic properties of platelet-activating factor: evidence for a direct mechanism in the contractile response of pulmonary tissues. 1983 Am. J. Pathol. pmid:6624879
Hartung HP Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7. 1983 FEBS Lett. pmid:6309563
Swendsen CL et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine: a novel source of arachidonic acid in neutrophils stimulated by the calcium ionophore A23187. 1983 Biochem. Biophys. Res. Commun. pmid:6407484
Bessin P et al. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. 1983 Eur. J. Pharmacol. pmid:6687572
Mueller HW et al. 1-O-alkyl-linked phosphoglycerides of human platelets: distribution of arachidonate and other acyl residues in the ether-linked and diacyl species. 1983 Lipids pmid:6419001
Shukla SD et al. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. 1983 J. Biol. Chem. pmid:6309795
Hallam TJ et al. The role of 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (AcGEPC) and palmitoyl-lysophosphatidate in the responses of human blood platelets to collagen and thrombin. 1983 FEBS Lett. pmid:6617886
Roussi J et al. [Success of treatment with a low-molecular-weight heparin fraction in a case of pulmonary embolism complicated by heparin-induced thrombopenia]. 1983 Nouv Rev Fr Hematol pmid:6622253
Valone FH and Goetzl EJ Enhancement of human polymorphonuclear leukocyte adherence by the phospholipid mediator 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine (AGEPC). 1983 Am. J. Pathol. pmid:6624880
Barradas MA et al. The effect of fenfluramine on collagen-induced platelet aggregation in vitro. 1983 Br J Clin Pharmacol pmid:6626443
Korth R et al. 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines: influence on aggregation and [3H]serotonin release of human thrombocytes. 1983 Chem. Phys. Lipids pmid:6627525
Moschidis MC et al. Phosphono-platelet activating factor I. Synthesis of 1-O-hexadecyl-2-O-acetyl-glyceryl-3-(2-trimethyl ammonium-methyl) phosphonate and its platelet activating potency. 1983 Chem. Phys. Lipids pmid:6627527
Vargaftig BB et al. Convulxin-induced activation of intact and of thrombin-degranulated rabbit platelets: specific crossed desensitisation with collagen. 1983 Eur. J. Pharmacol. pmid:6628537
Farr RS et al. Human serum acid-labile factor is an acylhydrolase that inactivates platelet-activating factor. 1983 Fed. Proc. pmid:6628702
Denjean A et al. Acute effects of intratracheal administration of platelet-activating factor in baboons. 1983 J Appl Physiol Respir Environ Exerc Physiol pmid:6629917
Camussi G et al. Biosynthesis and release of platelet-activating factor from human monocytes. 1983 Int. Arch. Allergy Appl. Immunol. pmid:6826235
Morley J et al. Inflammatory actions of platelet activating factor (Pafacether) in guinea-pig skin. 1983 Br. J. Pharmacol. pmid:6685552
Hornby EJ and Perry CR 1-O-hexadecyl-2-acetyl-sn-3-glycerophosphorylcholine (PAF): some effects on the aggregation of human platelets by thrombin or collagen. 1983 Thromb. Haemost. pmid:6636035
Patterson R and Harris KE The activity of aerosolized and intracutaneous synthetic platelet activating factor (AGEPC) in rhesus monkeys with IgE-mediated airway responses and normal monkeys. 1983 J. Lab. Clin. Med. pmid:6644157
Nunn B Total and selective desensitisation of human platelets to synthetic platelet activating factor (PAF): evidence that extracellular PAF does not mediate collagen-induced aggregation. 1983 Thromb. Res. pmid:6648898
Myers A et al. Glucocorticoid protection against PAF-acether toxicity in mice. 1983 Br. J. Pharmacol. pmid:6652344
Cervoni P et al. Aortic vascular and atrial responses to (+/-)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. 1983 Br. J. Pharmacol. pmid:6652348
Ogihara T et al. [Renomedullary hypotensive lipids and prostaglandins]. 1983 Horumon To Rinsho pmid:6368051
Benveniste J et al. The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. 1983 Br. J. Pharmacol. pmid:6652376
Garcia Gil M and Sanchez Crespo M Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes. 1983 Immunopharmacology pmid:6654649
Tokumura A et al. Biphasic action of platelet-activating factor on isolated guinea-pig ileum. 1983 Lipids pmid:6656539
Hamasaki Y et al. [Effects of platelet activating factor (PAF:AGEPC) on airway and pulmonary vascular constriction of guinea pigs--with special reference to the relation with TXA2]. 1983 Kokyu To Junkan pmid:6658209
Björk J et al. Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds. 1983 Acta Physiol. Scand. pmid:6659994
Björk J and Smedegård G Acute microvascular effects of PAF-acether, as studied by intravital microscopy. 1983 Eur. J. Pharmacol. pmid:6662199
Yamashita M et al. The metabolism of platelet activating factor in platelets and plasma of various animals. 1983 J Toxicol Sci pmid:6663653
Masugi F et al. [Kidney medulla and hypertension, with special reference to antihypertensive lipids]. 1983 Nihon Jinzo Gakkai Shi pmid:6663856
Tanaka S et al. Studies on the hypotensive effects of platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) in rats, guinea pigs, rabbits, and dogs. 1983 J. Pharmacobio-dyn. pmid:6668545
Saeki S et al. Hypotensive activity of 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine in rats with various types of hypertension. 1983 Med J Osaka Univ pmid:6669136
Mueller HW et al. Biosynthesis of platelet activating factor in rabbit polymorphonuclear neutrophils. 1983 J. Biol. Chem. pmid:6406476
Lee TC et al. Stimulation of calcium uptake by 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in rabbit platelets: possible involvement of the lipoxygenase pathway. 1983 Arch. Biochem. Biophys. pmid:6407399
Billah MM and Johnston JM Identification of phospholipid platelet-activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. 1983 Biochem. Biophys. Res. Commun. pmid:6407483
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Valone FH and Goetzl EJ Specific binding by human polymorphonuclear leucocytes of the immunological mediator 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycero-3-phosphorylcholine. 1983 Immunology pmid:6848449
Chilton FH et al. Metabolic fate of platelet-activating factor in neutrophils. 1983 J. Biol. Chem. pmid:6853486
Stormorken H et al. A new bleeding disorder: lack of platelet aggregatory response to adrenaline and lack of secondary aggregation to ADP and platelet activating factor (PAF). 1983 Thromb. Res. pmid:6857589
Kloprogge E et al. Stimulus-response coupling in human platelets. Evidence against a role of PAF-acether in the "third pathway'. 1983 Thromb. Res. pmid:6857605
Chilton FH et al. Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils. 1983 J. Biol. Chem. pmid:6408071
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Gonzalez-Crussi F and Hsueh W Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. 1983 Am. J. Pathol. pmid:6859226
Camussi G et al. Acute lung inflammation induced in the rabbit by local instillation of 1-0-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or of native platelet-activating factor. 1983 Am. J. Pathol. pmid:6859232
Sánchez-Crespo M et al. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. 1983 Am. J. Physiol. pmid:6859262
Lumb RH et al. Spontaneous and protein-catalyzed transfer of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) between phospholipid bilayers. 1983 Biochim. Biophys. Acta pmid:6860678
Suquet CM and Leid RW Aggregation of equine platelets by PAF (platelet-activating factor). 1983 Inflammation pmid:6862593
Blank ML and Snyder F Improved high-performance liquid chromatographic method for isolation of platelet-activating factor from other phospholipids. 1983 J. Chromatogr. pmid:6863454
Simrock R et al. [Reversible inhibition of thrombocyte stimulation by acetylsalicylic acid and its role in antithrombotic therapy]. 1983 Klin. Wochenschr. pmid:6865264
Hadváry P and Baumgartner HR Activation of human and rabbit blood platelets by synthetic structural analogs of platelet activating factor. 1983 Thromb. Res. pmid:6868019
O'Flaherty JT and Wykle RL Biology and biochemistry of platelet-activating factor. 1983 Clin Rev Allergy pmid:6370406
Hubbard JW et al. Antihypertensive effects of I-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine on plasma renin activity and catecholamine responses in spontaneously hypertensive rats. 1983 Life Sci. pmid:6337313
Acharya SB and MacIntyre DE Platelet products and vascular PGI2 production. 1983 Prostaglandins Leukot Med pmid:6338532
Camussi G et al. Effect of prostacyclin (PGI2) on immune-complex-induced neutropenia. 1983 Immunology pmid:6339375
Billah MM and Lapetina EG Platelet-activating factor stimulates metabolism of phosphoinositides in horse platelets: possible relationship to Ca2+ mobilization during stimulation. 1983 Proc. Natl. Acad. Sci. U.S.A. pmid:6341992
Lapetina EG and Siegel FL Shape change induced in human platelets by platelet-activating factor. Correlation with the formation of phosphatidic acid and phosphorylation of a 40,000-dalton protein. 1983 J. Biol. Chem. pmid:6345519
Camussi G et al. Inhibitory effect of prostacyclin (PGI2) on neutropenia induced by intravenous injection of platelet-activating-factor (PAF) in the rabbit. 1983 Prostaglandins pmid:6346397
Iñarrea P et al. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. 1983 Immunopharmacology pmid:6347969
Satouchi K [Platelet activating factor (PAF)--a new chemical mediator of inflammation]. 1983 Seikagaku pmid:6350499
McGowan EB and Detwiler TC Characterization of the thrombin-induced desensitization of platelet activation by thrombin. 1983 Thromb. Res. pmid:6356458
Weksler BB Platelets and the inflammatory response. 1983 Clin. Lab. Med. pmid:6360503
Machin SJ et al. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. 1983 J. Clin. Pathol. pmid:6413552
Alam I et al. Metabolism of platelet-activating factor by blood platelets and plasma. 1983 Lipids pmid:6413803
Pinckard RN Platelet-activating factor. 1983 Hosp. Pract. (Off. Ed.) pmid:6414941
Camussi G et al. The release of platelet-activating factor from human endothelial cells in culture. 1983 J. Immunol. pmid:6415166
Bonnet J et al. Dependency of the Paf-acether induced bronchospasm on the lipoxygenase pathway in the guinea-pig. 1983 Prostaglandins pmid:6419289
Pazzi A et al. [Platelet activation in vivo. Electron microscopy study of a case of type II diabetes]. 1983 Mar-Apr G Clin Med pmid:6884636
Mojarad M et al. Platelet-activating factor increases pulmonary microvascular permeability and induces pulmonary edema. A preliminary report. 1983 May-Jun Bull Eur Physiopathol Respir pmid:6882949
Hillmar I et al. Effects of a thio analog of platelet-activating factor on platelet aggregation and adenosine 3',5'-monophosphate concentration in hepatocyte suspensions and in platelets. A comparison with the naturally occurring compound. 1984 Hoppe-Seyler's Z. Physiol. Chem. pmid:6325321
Valone FH Isolation of a platelet membrane protein which binds the platelet-activating factor 1-0-hexadecyl-2-acetyl-SN-glycero-3-phosphorylcholine. 1984 Immunology pmid:6325330
Lefort J et al. The platelet-independent release of thromboxane A2 by Paf-acether from guinea-pig lungs involves mechanisms distinct from those for leukotriene. 1984 Br. J. Pharmacol. pmid:6430375
Gómez-Cambronero J et al. The role of calcium ions in the process of acetyltransferase activation during the formation of platelet-activating factor (PAF-acether). 1984 Biochem. J. pmid:6146309
Morley J et al. The platelet in asthma. 1984 Lancet pmid:6150192
Dahlbäck M et al. Bronchial anaphylaxis in actively sensitized Sprague Dawley rats: studies on mediators involved. 1984 Acta Pharmacol Toxicol (Copenh) pmid:6431753
Willoughby WF and Willoughby JB Immunologic mechanisms of parenchymal lung injury. 1984 Environ. Health Perspect. pmid:6234162
Saeki S et al. Effect of 1-hexadecyl-2-acetyl-sn-glycero-3-phosphorylcholine on blood pressure by intra-lateral ventricular injection in the rat. 1984 Med J Osaka Univ pmid:6482814
Jouvin-Marche E et al. Biosynthesis of Paf-acether (platelet-activating factor). VII. Precursors of Paf-acether and acetyl-transferase activity in human leukocytes. 1984 J. Immunol. pmid:6736649
Renal syndromes and nonsteroidal antiinflammatory drugs. 1984 N. Engl. J. Med. pmid:6738607
Williams KA and Haslam RJ Effects of NaCl and GTP on the inhibition of platelet adenylate cyclase by 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (synthetic platelet-activating factor). 1984 Biochim. Biophys. Acta pmid:6696908
Hoffman DR et al. Cytotoxicity of platelet activating factor and related alkyl-phospholipid analogs in human leukemia cells, polymorphonuclear neutrophils, and skin fibroblasts. 1984 Blood pmid:6696992
O'Neill C and Saunders DM Assessment of embryo quality. 1984 Lancet pmid:6149413
Prevost MC et al. Platelet activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia. 1984 Biochem. Biophys. Res. Commun. pmid:6422938